Drug Development, Protocols

Protocols: RaNA recruits Shire vet as new CSO; Catalent buys Pharmatek

The Cambridge, MA-based RNA expert RaNA Therapeutics has recruited Thomas McCauley, a Shire vet, as its new CSO.

Somerset, NJ-based Catalent has bought up Pharmatek Laboratories, a drug development and clinical manufacturing operation. The acquisition will add some additional tech for formulation and delivery, with a network that specializes in early-stage work. Pharmatek has a cGMP facility in San Diego that employs nearly 200 people.

Evanston, IL-based Aptinyx nabbed fast track status for its lead compound, NYX-2925, as a treatment for neuropathic pain associated with diabetic peripheral neuropathy.

San Diego-based AmpliPhi Biosciences has put out top line data from a Phase I safety study of AB-SA01, a cocktail targeting Staphylococcus aureus (S. aureus) infections. Investigators say the cocktail was well tolerated.

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017